Evidence map›Paper›PMID 28529649›Full record

ArticleTheranostics2017

SAK-HV Triggered a Short-period Lipid-lowering Biotherapy Based on the Energy Model of Liver Proliferation via a Novel Pathway.

Chao Zhang, Zhiguang Huang, Haoran Jing, Wenliang Fu, Min Yuan, Wenrong Xia, Ling Cai, Xiangdong Gan, Yao Chen, Minji Zou and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution.

Chao ZhangLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Zhiguang HuangLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Haoran JingLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Wenliang FuLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Min YuanLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Wenrong XiaLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Ling CaiLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Xiangdong GanLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Yao ChenLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Minji ZouLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Minhui LongLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Jiaxi WangLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Min WangLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Donggang XuLaboratory of Genome Engineering, Beijing Institute of Basic Medical Sciences, Beijing, PR China.
Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accumulations of excess lipids within liver and serum are defined as non-alcoholic fatty liver disease (NAFLD) and hyperlipemia respectively. Both of them are components of metabolic syndrome that greatly threaten human health. Here, a recombinant fusion protein (SAK-HV) effectively treated NAFLD and hyperlipemia in high-fat-fed

Indexed as

AnimalsAnticholesteremic AgentsBiological TherapyDisease Models, AnimalEstrogensHirudinsHyperlipidemiasLiverMetalloendopeptidasesMiceNon-alcoholic Fatty Liver DiseasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaQuailRatsRecombinant Fusion ProteinsTreatment OutcomeAnticholesteremic AgentsauR protein, Staphylococcus aureusEstrogensHirudinsMetalloendopeptidasesPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaRecombinant Fusion Proteinsbiotherapy.estrogenhyperlipemialiver proliferationnon-alcoholic fatty liver disease (NAFLD)PGC-1α

Identifiers

PMID28529649
PMCPMC5436525
OpenAlexW2610756091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.